HENDERSON, Nev., July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program,  tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The results correlated strongly with those of Volition's established automated central la ...

To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon's CMO for CNS, will f ...

MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan- McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phe ...

Informa Connect’s Global Longevity Summit continues to break new ground in the science of aging and human performance with the announcement of its 2025 keynote speaker, new advisory board appointments, and a call to act before the upcoming ticket price increase.GENEVA, SWITZERLAND, June 12, 2025 (GLOBE NEWSWIRE) -- Biogerontologist and epigenetic researcher Dr. Steve Horvath will headline the event as its keynote speaker and will be formally recognized as the recipient of the 2025 Global Longevity Award for ...

Core Insights - VolitionRx Limited is presenting its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025) in Thailand, highlighting its potential as a diagnostic tool for veterinary oncology [1][2] - The test has shown promise in differentiating between benign and malignant conditions, particularly Canine Chronic Enteropathy and Gastrointestinal Lymphoma, according to Dr. Masahiko Sato [2] - The company aims to enhance awareness and adoption of the Nu.Q® Vet Cancer Test through clinical research and presentations by leading veterinarians [2] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [3] - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, with the goal of prolonging life and improving quality of life for patients [4] - Volition's research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [5]

Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several international events in May-June. Oryzon will attend the Foro Medcap 2025, which will take place at the Madrid Stock Exchange palace in Ma ...

Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be ...

Core Insights - Illumina Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of 97 cents, exceeding the Zacks Consensus Estimate by 1%, but down 1% year-over-year [1] - The company's GAAP EPS was 82 cents, reflecting an 86.4% increase year-over-year [1] Revenue Performance - Revenues for the first quarter amounted to $1.04 billion, a decrease of 1.4% year-over-year, but slightly above the Zacks Consensus Estimate by 0.2% [2] - The stock fell 2.2% in after-market trading following the earnings announcement [2] Segment Analysis - Core Illumina's sequencing service and other revenues totaled $142 million, down 5% year-over-year, primarily due to timing of strategic partnership revenues [3] - Sequencing consumable revenues reached $696 million, up 1% year-over-year, driven by high-throughput consumables [3] Margin and Expense Overview - Adjusted gross margin was 67.2%, an increase of 79 basis points year-over-year, attributed to a 5.5% decline in the cost of revenues [4] - Research and development expenses decreased by 25.7% year-over-year to $252 million, while SG&A expenses totaled $267 million, down 39.2% from the previous year [4] - Adjusted operating profit for the quarter was $181 million, compared to an operating loss of $63 million in the same quarter last year [4] Financial Position - At the end of Q1 2025, Illumina had cash and cash equivalents of $1.11 billion, slightly down from $1.13 billion at the end of Q4 2024 [5] - Cumulative net cash provided by operating activities was $240 million, compared to $77 million a year ago [5] 2025 Guidance - For 2025, Illumina expects Core Illumina revenues to decline by 1%-3% on a constant currency basis, revised from earlier low single-digit growth expectations [6] - The Zacks Consensus Estimate for 2025 revenues is currently $4.31 billion [6] - Non-GAAP diluted EPS is projected to be in the range of $4.20-$4.30, down from the previous estimate of $4.50-$4.65 [7] Key Developments - Illumina made significant announcements in Q1, including innovations in genomics, spatial transcriptomics, and collaborations with Broad Clinical Labs and the Broad Institute [8][9] - The company sequenced 250,000 whole genomes for the Alliance for Genomic Discovery initiative [9] Overall Assessment - Illumina's earnings and revenues beat estimates, with positive progress in the NovaSeq X transition among clinical customers [10] - Despite the positive aspects, both top and bottom lines showed year-over-year declines, reflecting the impact of evolving policy and geopolitical developments [11]

Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstatOryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancersFunding covers 64% of Oryzon’s VANDAM project total budgetFurther reinforces Oryzon’s robust financial standing M ...

HENDERSON, Nev., April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds, has issued a Shareholder Letter providing a business update.A Message from our Chief Executive Officer2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market. I am delighted to report we are in confidential di ...